Rgenix is made possible through financing from investors including Novo A/S, Sofinnova Partners, Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP.
Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.